• Product nameAnti-NALP1 antibody
    See all NALP1 primary antibodies
  • Description
    Rabbit polyclonal to NALP1
  • Tested applicationsSuitable for: WB, IHC-P, ICCmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide conjugated to KLH, corresponding to 13 amino acids near the C terminus of Human NALP1 (NP_055737.1).

  • Positive control
    • Human Brain, Cortex tissue.



Our Abpromise guarantee covers the use of ab115580 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 166 kDa.
IHC-P Use a concentration of 2.5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC Use at an assay dependent concentration.


  • FunctionAble to form cytoplasmic structures termed death effector filaments. Enhances APAF1 and cytochrome c-dependent activation of pro-caspase-9 and consecutive apoptosis. Stimulates apoptosis through activation of caspase-3. Involved in activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Binds ATP.
  • Tissue specificityWidely expressed. Isoform 1 and isoform 2 are expressed in peripheral blood leukocytes and chronic myelogenous leukemia cell line K-562, followed by thymus, spleen and heart. Also detected in brain, lung, placenta, small intestine, colon, kidney, liver, muscle, testis and epithelial cells. Absent from hematopoietic progenitor cells but expressed upon differentiation of cells into granulocytes and, to a lesser extent, monocytes. In peripheral blood cells, highest levels are found in T-lymphocytes, granulocytes and monocytes. Expression is significantly increased in bone marrow blast cells of some acute leukemia patients but not in solid tumors.
  • Involvement in diseaseGenetic variations in NLRP1 are associated with susceptibility to vitiligo (VTLG) [MIM:193200]. VTLG is a pigmentary disorder of the skin characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. It is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.
    Genetic variations in NLRP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1 (VAMAS1) [MIM:606579]. VAMAS1 is an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
  • Sequence similaritiesBelongs to the NLRP family.
    Contains 1 CARD domain.
    Contains 1 DAPIN domain.
    Contains 6 LRR (leucine-rich) repeats.
    Contains 1 NACHT domain.
  • Cellular localizationCytoplasm. Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CARD 7 antibody
    • CARD7 antibody
    • Caspase recruitment domain protein 7 antibody
    • Caspase recruitment domain-containing protein 7 antibody
    • CLR17.1 antibody
    • Death effector filament forming Ced 4 like apoptosis protein antibody
    • Death effector filament-forming ced-4-like apoptosis protein antibody
    • DEFCAP antibody
    • DEFCAP L/S antibody
    • DKFZp586O1822 antibody
    • KIAA0926 antibody
    • LRR and PYD domains-containing protein 1 antibody
    • NAC alpha/beta/gamma/delta antibody
    • NAC antibody
    • NACHT antibody
    • NACHT leucine rich repeat and PYD containing 1 antibody
    • NACHT leucine rich repeat and PYD pyrin domain containing 1 antibody
    • NACHT leucine rich repeat and pyrin domain containing 1 antibody
    • NACHT LRR and PYD containing protein 1 antibody
    • NALP 1 antibody
    • NALP1 antibody
    • NALP1_HUMAN antibody
    • NLR family pyrin domain containing 1 antibody
    • NLRP 1 antibody
    • NLRP1 antibody
    • NLRP1 protein antibody
    • Nucleotide binding domain and caspase recruitment domain antibody
    • Nucleotide binding oligomerization domain leucine rich repeat and pyrin domain containing 1 antibody
    • Nucleotide-binding domain and caspase recruitment domain antibody
    • PP 1044 antibody
    • PP1044 antibody
    see all

Anti-NALP1 antibody images

  • ab115580, at 2.5 µg/ml, staining NAPL1 in Formalin-fixed, Paraffin-embedded Human Brain cortex tissue by Immunohistochemistry followed by biotinylated secondary antibody, alkaline phosphatase-streptavidin and chromogen.

References for Anti-NALP1 antibody (ab115580)

ab115580 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab115580.
Please use the links above to contact us or submit feedback about this product.